Cannabis operator Vext Science's Q1 revenue rises 5%, Ohio sales up 34%

Vext Science

21/05/2026 11:38

Overview

U.S. cannabis operator's Q1 revenue rose 5% yr/yr, adjusted EBITDA increased sharply

Ohio revenue grew 34% yr/yr, driven by improved cultivation yields

Arizona repositioning underway as company exits Eloy cultivation amid market oversupply

Outlook

Company expects business to generate strong cash flow through 2026 and beyond

Arizona cultivation exit expected to complete by end of Q2 2026

Result Drivers

OHIO GROWTH - Ohio revenue rose 34% yr/yr, driven by improved cultivation yields and expansion to five dispensaries

ARIZONA REPOSITIONING - Co is exiting cultivation in Arizona due to market oversupply and price compression, focusing on dispensaries and manufacturing

Company press release: ID:nNFCbN6C4F

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$12.16 mln
$12.4 mln (2 Analysts)
Q1 Adjusted EBITDA
$3.56 mln
$2.7 mln (2 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Vext Science Inc is C$0.40, about 45.5% above its May 20 closing price of C$0.28

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)